Methods The CHARM Program
The design and main results of the CHARM Program have been previously reported. [10] [11] [12] [13] [14] Briefly, CHARM consisted of 3-component randomized, double-blind, controlled trials comparing candesartan to placebo in 7599 subjects with symptomatic HF (New York Heart Association II-IV) treated with standard HF therapy. The CHARM-Alternative trial (http://www.clinicaltrials.gov, NCT 00634400) enrolled 2028 subjects with left ventricular ejection fraction (EF) ≤40% and previous intolerance of angiotensin-converting enzyme-inhibitors with no requirement for prior hospitalization. The CHARM-Added (NCT 00634309) trial enrolled 2548 subjects with left ventricular EF ≤40% who were treated with an angiotensin-converting enzyme-inhibitor at baseline; to be eligible, those subjects with New York Heart Association II symptoms were required to have a CV hospitalization within 6 months before randomization. The CHARM-Preserved trial (NCT 00634712) enrolled 3023 subjects with left ventricular EF >40%, all of whom had a previous history of CV hospitalization. All participating sites obtained approval from local ethics committees or institutional review boards for the conduct of each of the 3-component trials, and all patients gave written informed consent before enrollment. The primary end point for the overall CHARM Program was all-cause mortality, whereas that for each of the component trials was the composite of CV death or HF hospitalization. The median follow-up duration for the overall trial was 37.7 months.
Investigators were asked to report all elective and non-elective hospitalizations during study follow-up and to assign the primary reason for each hospitalization to 1 of several predefined CV (worsening HF, hypotension, myocardial infarction, unstable angina, transient ischemic attack, stroke, atrial tachyarrhythmia, ventricular tachyarrhythmia, other) or non-CV (cancer, other) categories. The 8069 hospitalizations assigned to the "other" categories contained free text descriptors of the primary cause that were individually reviewed by an experienced cardiologist (A.S. Desai) and used to design an algorithm reclassify the admission as possible into specific CV (as above) or non-CV categories (gastrointestinal, infectious, orthopedic/ rheumatologic, cancer, renal, pulmonary, endocrine, neurological/ psychiatric, urologic/gynecologic). The specific algorithm and programming code used to perform the reclassification are provided in the Data Supplement.
Statistical Analysis
The proportion of first hospitalizations attributable to CV and non-CV causes was tabulated for the overall CHARM program. Hospitalizations carrying both CV and non-CV descriptors were assigned to the CV category. Subjects in whom the date of death coincided with the date of the hospitalization were classified as not hospitalized. Baseline characteristics for hospitalized and non-hospitalized patients and for hospitalization by cause were compared using standard chi-squared tests for categorical variables and t tests for continuous variables.
Crude rates of all-cause mortality after first hospitalization for CV or non-CV reasons were compared in time-updated Cox proportional hazards models. 15 Adjusted hazard ratios for mortality were also generated after controlling for baseline predictors of all-cause mortality identified in previous CHARM analyses. 16 Because of the timedependent risk of death associated with hospitalizations and violation of traditional proportional hazards assumptions, death rates were examined within 30 days of incident hospitalization and separately in 30-day survivors of hospitalization to discriminate the effect of nonfatal hospitalization events on subsequent prognosis. Analyses were replicated in subgroups with reduced (≤40%) and preserved (>40%) EF.
To assess the effect of cumulative CV and non-CV hospitalizations on subsequent prognosis, we compared death rates among the following groups of patients according to their time-updated hospitalization status: those not hospitalized, those hospitalized once for CV or non-CV reasons, and those with ≥2 hospitalizations during the trial. Death rates in those with ≥2 hospitalizations were calculated separately for those whose first 2 hospitalizations were both for CV reasons, those whose first 2 hospitalizations were both for non-CV reasons, and those with 1 hospitalization of each type.
All analyses were conducted using STATA statistical software (version 13, College Station, TX). The authors (A.S. Desai and B. Claggett) had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis.
Results

Hospitalizations in CHARM-Overall
Of 7599 subjects enrolled in the CHARM program, 2816 (37.1%) were not hospitalized during the course of trial followup. Of the remaining 4783 subjects with ≥1hospitalization, 2893 (38.1%) were first hospitalized for CV reasons and 1890 (24.9%) were first hospitalized for non-CV reasons. Among those first hospitalized for CV reasons, hospitalization for HF management accounted for 998 (34.5%), acute coronary syndromes for 556 (19.2%), arrhythmias for 263 (9.1%), and stroke/transient ischemic attack for 175 (6.0%). The most commonly reported specific non-CV causes of first hospitalization were pneumonia/respiratory tract infection, cancer, chronic obstructive pulmonary disease/bronchitis, cholelithiasis/biliary colic, renal failure, anemia, dizziness/vertigo, hyperkalemia, dehydration, and pancreatitis. In aggregate, gastrointestinal, infectious, and orthopedic/rheumatologic problems accounted for nearly half of the first non-CV hospitalizations ( Figure 1 ).
Baseline characteristics according to type of first hospitalization are reported in Tables 1 and 2. Characteristics of the patients who died without hospitalization are separately reported in Table I in the Data Supplement. Hospitalized patients were older with more severe HF and more comorbidities than those who were not hospitalized ( Table 1) . Patients hospitalized first for CV reasons were similar to those hospitalized first for non-CV reasons, but were younger, had lower EF, and were more commonly men with a prior history of myocardial infarction and angina ( Table 2 ).
Effect of First Hospitalization on Subsequent Mortality
The crude death rate (per 100 patient-years) among those not hospitalized was 2. Figure 1 ). The RR for death associated with first CV and non-CV hospitalization persisted after multivariable adjustment for baseline predictors of mortality, including age, EF, diabetes mellitus, body mass index, New York Heart Association class, sex, smoking, prerandomization history of HF hospitalization, and treatment assignment (adjusted hazard ratio [HR] 6.44 for CV [95% CI, 5.65-7.33], adjusted HR 6.14 for non-CV [95% CI, 5.33-7.08]). Further adjustment for country of origin did not substantively alter these findings (results not shown). Among those hospitalized for CV reasons, death rates were highest for those hospitalized for stroke (34.5 per 100 patient-years; 95% CI, 26.6-46.6), HF (28.6 per 100 patient-years; 95% CI, 26.1-33.3), and myocardial infarction (25.6 per 100 patient-years; 95% CI, 19.9-32.9); among those first hospitalized for non-CV reasons, death rates were highest for cancer (43.9 per 100 patient-years; 95% CI, 34.7-55.5), pulmonary disease (23.3 per 100 patient-years; 95% CI, 17.5-31.0), and renal disease (21.2 per 100 patient-years; 95% CI, 16.0-28.1; Figure 1 ).
First Hospitalization in Preserved Versus Reduced EF Subgroups
The incidence of first hospitalization for CV reasons was higher in patients with EF ≤40% than those with EF >40% (23.6 versus 19.3 per 100 patient-years; P<0.001), but the incidence of non-CV hospitalization was similar in both EF subgroups (Table 3) . Accordingly, the proportion of first hospitalizations related to non-CV reasons was highest in patients with preserved EF and declined with lower EF (Figure 2 ). Among those first hospitalized for CV reasons, the proportion hospitalized for HF was lower in patients with HF and preserved EF than in those with HF and reduced EF ( Table 3 ). Similar results were apparent in sensitivity analyses restricted to the subset of patients with a history of HF hospitalization before enrollment in the trial, the subset of CHARM-preserved patients with EF >50%, and the subset of CHARM low EF subjects treated with an angiotensin-converting enzyme-inhibitor and β-blocker at baseline (Tables II-IV in the  Data Supplement) .
Cumulative Hospitalizations
During the course of trial follow-up, a cumulative total of 14 740 hospitalizations was recorded in CHARM, including 8965 (60.8%) for CV reasons and 5775 (39.2%) for non-CV reasons. Relative to placebo, treatment with candesartan was associated with a reduction in total hospitalizations and in the proportion of hospitalizations because of CV reasons (58.6% versus 62.9% for candesartan versus Placebo; P<0.001), but treatment did not influence the risk of death after first hospitalization (HR, 0.93; 95% CI, 0.84-1.03; P=0.146). The detailed breakdown of patients by first and subsequent hospitalization status is reported in Figure 3 . Death rates among those hospitalized once for CV reasons were higher than those hospitalized once for non-CV reasons. However, among those with ≥2 hospitalizations, death rates were similar for those whose first 2 hospitalizations were for CV reasons, those whose first 2 hospitalizations were for non-CV reasons, and those with 1 of each type (Figure 3 ).
Discussion
In this population of symptomatic HF patients across broad range of EFs, nearly a third of whom were previously hospitalized for HF exacerbation, we found that non-CV reasons accounted for nearly 40% of first hospital admissions. The incidence of non-CV hospitalization was nearly constant across EF categories, whereas that of CV hospitalization declined with increasing EF; accordingly, the proportion of total admissions attributable to non-CV causes increased with EF. Although the CHARM trial systematically enrolled patients with symptomatic HF, the minority of CV hospitalizations during trial follow-up were related to HF exacerbation. Hospitalization for any reason was associated with high risk for subsequent mortality, with higher risk in low than preserved EF patients. Early mortality was higher after first CV than first non-CV hospitalization, but rates of mortality in 30-day survivors were similar in both groups. Cumulative hospitalizations increased the risk of death, but death rates were similar in patients with ≥2 CV hospitalizations, ≥2 non-CV hospitalizations, and those with ≥1 of each type.
Non-CV comorbidities, including chronic obstructive pulmonary disease, chronic kidney disease, diabetes mellitus, depression, and dementia, are common in patients with HF and frequently precipitate, contribute to, or complicate HF exacerbation and the need for hospital admission. [17] [18] [19] [20] [21] The burden of comorbidities seems to be closely linked to the risk for hospital admission, particularly in the elderly and in those with preserved EF, 20, 22 and is an important driver of healthcare costs. 23, 24 In a cross-sectional analysis of 122 630 Medicare patients with HF over the age of 65 years, >80% of the total inpatient hospital days during follow-up were accounted for by the 40% of subjects with ≥5 noncardiac comorbidities. 20 Our data confirms and extends previous data from published registries, 25 randomized trials, [26] [27] [28] and community dwelling populations, 1 highlighting the substantial contribution of non-CV hospitalization to the overall burden of hospitalization in HF patients. Notably, patients hospitalized for non-CV reasons were not easily distinguished from those hospitalized for CV reasons by their demographic or clinical characteristics. As well, these analyses underscore the greater proportionate contribution of non-CV hospitalization to morbidity in those with HF and preserved EF, for whom noncardiac illness may be a particularly important target for therapy. 22, 29 Although unplanned hospitalization for HF management is known to be an important predictor of the risk for subsequent mortality both in CHARM 8 and in other populations, 7 these hospitalizations accounted for fewer than one hird of total hospitalizations recorded during the period of trial follow-up in CHARM. Our analysis is novel in its focus on the prognostic relevance of the balance of non-HF-related hospitalization events. That hospitalization for CV reasons more generally is associated with poor prognosis, particularly in the early postdischarge interval, is less surprising than the finding that 30-day survivors of non-CV and CV hospitalization have similar rates of subsequent death. There are several potential explanations for the risk associated with non-CV hospitalization in HF patients. First, the need for hospitalization to manage non-CV issues may mark patients with a larger overall burden and severity of medical illness that is itself associated with risk for death in HF patients. Second, exacerbations of comorbidities, such as obstructive lung disease and chronic kidney disease, may directly contribute to worsening HF severity and compromise subsequent outcomes. Finally, patients with a large burden of comorbidities may be less able to tolerate optimal HF treatement or experience difficulties with adherence to the prescribed medical program.
Whatever the specific explanation, the finding that hospitalization for any cause has similar prognostic relevance in HF patients should draw attention from those interested in improving the quality and reducing the overall costs associated with HF care. To date, most HF disease management strategies have heavily emphasized appropriate application of guideline-directed medical therapies and aggressive management of filling pressures to relieve congestive symptoms and improve outcomes. Although these strategies are undoubtedly important, such intensive focus on refining the management of a single severe, chronic medical condition may detract from attention to seemingly unrelated conditions that can also powerfully affect subsequent outcomes. 30 Available data suggests that many non-CV admissions may be related to ambulatory caresensitive conditions and are therefore potentially preventable. 20 In this context, inadvertent neglect of comorbid medical illness in HF patients may represent a missed-opportunity for reducing hospital admissions and improving HF care. 19 Our analysis must be viewed in the context of its limitations. First, we focused on the effect of the first admission during follow-up in CHARM on subsequent prognosis. Because many patients had both CV and non-CV admissions over the course of trial follow-up, this analysis may be vulnerable to overstating the effect of non-CV admissions on subsequent mortality. However, similar results in the time-varying models exploring the effect of cumulative rates of CV and non-CV hospitalization suggest that our findings regarding the prognostic relevance of non-CV hospitalization are robust. Second, like all clinical trial populations, patients in CHARM represent a selected population of HF patients, including some previously hospitalized for CV reasons; accordingly, these results may not be generalizable to community HF populations with no prior experience of hospitalization. Finally, because we identified the primary reason for hospitalization based on investigator report, we cannot exclude the possibility that some CV hospitalizations may have been misclassified as non-CV and vice-versa. Although some may challenge our algorithm for categorizing CV and non-CV hospitalization (see appendix), comparable rates of CV and non-CV hospitalization reported here from CHARM to those previously reported in other HF populations argue against any systematic error in category assignment. In summary, we found that a substantial portion of the morbidity and risk of mortality in patients with HF is related to non-CV hospitalizations. These findings suggest the need for approaches to HF disease management that focus more comprehensively on the treatment of both CV and non-CV comorbidities, rather than exclusively on HF management. 31 Though the optimal model for care delivery has yet to be defined, there is increasing evidence to support strategies that leverage the combined expertise of both primary care providers and CV experts. 32 Embedding HF disease management within integrated care delivery models, such as the patient-centered medical home, may be an important step to making a sustained effect on HF readmission rates.
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